Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Immunity. 2018 Mar 20;48(3):500-513.e6. doi: 10.1016/j.immuni.2018.02.013. Epub 2018 Mar 13.
Virtually the entire surface of the HIV-1-envelope trimer is recognized by neutralizing antibodies, except for a highly glycosylated region at the center of the "silent face" on the gp120 subunit. From an HIV-1-infected donor, #74, we identified antibody VRC-PG05, which neutralized 27% of HIV-1 strains. The crystal structure of the antigen-binding fragment of VRC-PG05 in complex with gp120 revealed an epitope comprised primarily of N-linked glycans from N262, N295, and N448 at the silent face center. Somatic hypermutation occurred preferentially at antibody residues that interacted with these glycans, suggesting somatic development of glycan recognition. Resistance to VRC-PG05 in donor #74 involved shifting of glycan-N448 to N446 or mutation of glycan-proximal residue E293. HIV-1 neutralization can thus be achieved at the silent face center by glycan-recognizing antibody; along with other known epitopes, the VRC-PG05 epitope completes coverage by neutralizing antibody of all major exposed regions of the prefusion closed trimer.
HIV-1 包膜三聚体的几乎整个表面都可被中和抗体识别,除了 gp120 亚基“静默面”中心高度糖基化的区域。我们从一位 HIV-1 感染者供体#74 中鉴定出了抗体 VRC-PG05,它能中和 27%的 HIV-1 株系。VRC-PG05 的抗原结合片段与 gp120 复合物的晶体结构揭示了一个主要由静默面中心 N262、N295 和 N448 的 N 连接聚糖组成的表位。抗体与这些糖基相互作用的残基上发生了体细胞超突变,提示了糖基识别的体细胞发育。供体#74 中对 VRC-PG05 的耐药性涉及糖基-N448 向 N446 的转移或糖基近端残基 E293 的突变。因此,糖基识别抗体可在静默面中心实现 HIV-1 的中和;加上其他已知的表位,VRC-PG05 表位完成了中和抗体对融合前封闭三聚体所有主要暴露区域的全覆盖。